Autopsy report · NCT04421378
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Cause of deathFunding or business
“Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time.”
Life of this trial
- Ran for about 3 years 1 month before it stopped.
- 74 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Karyopharm Therapeutics Inc
- Sponsor type
- Industry
- Conditions
- Glioblastoma Multiforme
- Interventions
- Selinexor; Temozolomide (TMZ); Lomustine (CCNU); Standard Fractionated Radiation therapy (RT); Bevacizumab; TTField
- Participants
- 74
- Sites
- 18
- Countries
- Canada, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.